Approval in US for Pfizer's renal cancer drug Inlyta - PMLiVE PDF Print
PMLiVE
The US Food and Drug Administration (FDA) has approved Pfizer's Inlyta as a second-line treatment for patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. On the same day, the FDA also started its review of Pfizer's bosutinib as

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129